Clinical Trial

A Study on the Modulation of Gut Microbiota by Oral Sialic Acid in Healthy Subjects

Study acronym: MFMOSA
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated December 10, 2025 (before its estimated August 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a single-center prospective cohort study conducted by the Department of General Surgery at the Second Affiliated Hospital of Army Medical University (Xinqiao Hospital). The purpose of this study is to explore and clarify the effects of sialic acid intervention on gut microbiota structure, with a focus on the proliferation of pathogens (e.g., Escherichia coli, Klebsiella pneumoniae), and to develop novel prevention and treatment strategies for improving intestinal homeostasis.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-09-07.
Trial Details
NCT Number NCT07162662
Lead Sponsor Xiaolong Li
Conditions Taking Sialic Acid to Regulate the Gut Microbiota, Healthy
Enrollment 42 participants
Start Date 2025-09-10
Primary Completion 2026-08-01 (estimated)
Study Completion 2027-08-01 (estimated)
Updated on ClinicalTrials.gov 2025-12-10